
Head & Neck Cancers
Latest News
Latest Videos

More News









Ezra Cohen, MD, discusses the future role of immunotherapy in the treatment of patients with head and neck squamous cell carcinoma.

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

Cisplatin plus radiotherapy results in better overall survival and the same rate of all-grade toxicity compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer.

Frontline pembrolizumab monotherapy showed an improvement in overall survival and duration of response versus standard therapy in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma; however, there was not a similar improvement in progression-free survival or overall response rate with the PD-1 inhibitor.

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.










The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options.


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the significance of the CheckMate-041 trial for patients with head and neck cancer.

















































































